tiprankstipranks
BioVaxys Secures Funding for Immunotherapy Growth
Company Announcements

BioVaxys Secures Funding for Immunotherapy Growth

Biovaxys Technology Corp (TSE:BIOV) has released an update.

BioVaxys Technology Corp. has successfully completed the first tranche of its non-brokered private placement, raising over $333,000 through the issuance of units at $0.065 each. These funds are earmarked for general working capital and to further the company’s business plans following its acquisition of a portfolio of immunological assets. Investors are also looking forward to the anticipated closing of the final tranche within the next two weeks, pending regulatory approval.

For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles